Next Generation Vaccines Conference, October 21-22 2010,Vienna, Austria
The vaccine market represents an increasingly attractive segment characterized by promising vaccine candidates, rising global demand and preparations for the next pandemic influenza. Future potential of the vaccine market will be discussed at Jacob Fleming’s Next Generation Vaccines Conference, taking place in Vienna, Austria on 21st – 22nd October. The latest developments in the prophylactic [...]
Cellular Immunotherapy for Men with Advanced Prostate Cancer
The U.S. Food and Drug Administration today approved Provenge (sipuleucel-T), a new therapy for certain men with advanced prostate cancer that uses their own immune system to fight the disease. Provenge is manufactured by Seattle-based Dendreon Corp. Provenge is indicated for the treatment of asymptomatic or minimally symptomatic prostate cancer that has spread to other [...]
DNA Vaccines 2010, March 2 - 4, 2010, New Orleans, LA
DNA Vaccines 2010 will be held March 2 - 4, 2010, at Sheraton New Orleans Hotel, New Orleans, LA. This meeting will follow the same successful pattern as the prior meeting for leading researcher to gather and report on the latest cutting edge research currently being undertaken in the progressive field of DNA or [...]
A New Trivalent Seasonal Influenza Candidate Vaccine Shows 78 Percent Rate of Prevention Against Matching Influenza Strains
Baxter International Inc., in conjunction with DynPort Vaccine Company LLC (DVC), announced Phase III study data measuring the clinical efficacy for PREFLUCEL, a trivalent seasonal influenza candidate vaccine. PREFLUCEL is made using Baxter’s Vero cell culture platform and does not contain an adjuvant or preservatives.
The Phase III clinical study found a 78 percent [...]
Leukemia Vaccine Shows Promise
BioSante Pharmaceuticals, Inc. announced positive results of a human clinical study that show that its GVAX Leukemia vaccine may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Gleevec (imatinib mesylate). BioSante owns the commercial rights to all GVAX vaccines as a result [...]
Cell-based Viral Vaccines: FDA Issues Final Guidance
To boost development of cell-based viral vaccines FDA issued final guidance. Today’s guidance outlines the best practices using current and emerging science to safely expand the types of cells that may be used to produce vaccines.
According to a recent market study “Global Pandemic Influenza Preparedness Market Forecast 2010-2015“, cell-based development will be the core of [...]
Anthrax Vaccine Contract for $78.4 Awarded by HHS
A biodefense company PharmAthene, Inc., specializing in the development and commercialization of medical countermeasures against chemical and biological threats, has been awarded additional contract for $78.4 by Department of Health and Human Services (HHS) to develop a second generation recombinant protective antigen (rPA) anthrax vaccine targeted for future procurement in the U.S. Strategic National [...]
Pneumococcal Disease Vaccine Approved by FDA
Prevnar 13, a pneumococcal 13-valent conjugate vaccine for infants and young children ages 6 weeks through 5 years, has been approved by FDA. The new vaccine extends the protection to six additional types of the disease causing bacteria. Prevnar 13 is the successor to Prevnar, the pneumococcal 7-valent conjugate vaccine licensed by the FDA in [...]
Gates Foundation Will Commit $10 Billion for Vaccine Development
Gates Foundation announced commitment of $10 billion over the next decade to help research, develop and deliver vaccines for the world’s poorest countries. The foundation used a model developed by a consortium led by the Institute of International Programs at the Johns Hopkins Bloomberg School of Public Health to project the potential impact of vaccines [...]
Government Commission Calls for Faster Vaccine Production Technologies
President Barack Obama declared H1N1 a national emergency this weekend, a status that will give the federal government greater flexibility and authority to contain the pandemic. But the current shortage of H1N1 vaccine underscores the severe lack of U.S. preparedness in responding to pandemics, whether through natural disease transmission or manmade bioterrorist attacks.
“Whether the threat [...]
